Business
NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
Investment led by Cinctive Co-Founder Richard Schimel underscores institutional confidence in NeOnc’s biotech pipelineCALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") fo
About this update from Neonc Technologies Holdings, Inc.
[{"type":"image","alt":"NeOnc Technologies Holdings, Inc.","displaySize":"","headline":null,"caption":"NeOnc Technologies Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/31EVIWakRB17XYBfbTJVvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38","width":300,"height":93}},"lazy":false},{"type":"text","content":"Investment led by Cinctive Co-Founder Richard Schimel underscores institutional confidence in NeOnc’s biotech pipeline","length":118,"tagName":"p"},{"type":"text","content":"CALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") for the purchase and sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares of common stock at a per share exercise price of $9.00 at a combined purchase price of $7.20, that is expected to result in gross proceeds of up to approximately $16 million to the Company. NeOnc currently intends to use the net proceeds from the offering for repayment of indebtedness, and for working capital and corporate purposes.","length":850,"tagName":"p"},{"type":"text","content":"The PIPE is led by a $10 million investment by Cinctive Capital Management LP, a multi-strategy investment firm with a focus on biotechnology and therapeutics. The transaction represents a significant vote of confidence from the firm's leadership, particularly Co-Founder and Co-Chief Investment Officer Rich Schimel. Building on this institutional endorsement, Cinctive’s leadership further underscores the strength of the investment.","length":439,"tagName":"p"},{"type":"text","content":"Amir F. Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies Holdings, Inc., stated: “This strategic investment from a firm of Cinctive Capital’s caliber validates our technological approach and the potential of our c...